Dare Bioscience, Inc.

8-K · dare-20260611.htm iXBRL

0001401914 2026-04-13 2026-04-13

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
 FORM 8-K
 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 11, 2026
 DARÉ BIOSCIENCE, INC.
 (Exact name of registrant as specified in its charter)
  

 Delaware   001-36395   20-4139823
 (State or other jurisdiction
of incorporation)   (Commission
File Number)   (I.R.S. Employer
Identification No.)

  
 3655 Nobel Drive , Suite 260
 San Diego , CA 92122
 (Address of Principal Executive Offices and Zip Code)
 Registrant’s telephone number, including area code: ( 858 )  926-7655
  
 Not Applicable
 (Former name or former address, if changed since last report.)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
    

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class Trading Symbol(s) Name of each exchange on which registered
 Common stock DARE Nasdaq Capital Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company   ¨
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 As reported in Item 5.07 below, at the 2026 annual meeting of stockholders of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) (the “Meeting”), our stockholders approved an amendment to the Daré Bioscience, Inc. 2022 Stock Incentive Plan (the “2022 Plan Amendment”) to increase the number of shares available for issuance thereunder by 1,500,000. Our board of directors previously approved the 2022 Plan Amendment, subject to and effective upon approval of the 2022 Plan Amendment by our stockholders. A brief description of the terms and conditions of the 2022 Plan Amendment is in the section entitled “Proposal 6 – To Approve an Amendment to the Company’s 2022 Stock Incentive Plan” of the definitive proxy statement for the Meeting filed with the U.S. Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”), which description is incorporated herein by reference. A copy of the 2022 Plan Amendment is filed as an exhibit to this report and incorporated by reference herein.

 Item 5.07 Submission of Matters to a Vote of Security Holders.

 The Meeting was held on June 11, 2026 and the following proposals were voted upon by our stockholders. The proposals are described in detail in the Proxy Statement. Below is a brief description of, and the final results of the votes for, each proposal.

 Proposal 1 : Each of the director nominees identified in the table below was elected as a Class III director to hold office until our 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.

 Nominee
 Votes For
 Votes Withheld
 Broker Non-Votes

 Gregory W. Matz, CPA
 3,752,211 403,510 3,822,158
 Sabrina Martucci Johnson
 3,848,085 307,636 3,822,158

 Proposal 2 : Our stockholders ratified the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 7,754,883 131,829 91,167 —

 Proposal 3 : Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 3,625,596 458,662 71,463 3,822,158

 Proposal 4 : Our stockholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of our named executive officers.

 Every year
 Every two years
 Every three years
 Abstentions
 Broker Non-Votes

 3,684,058 64,201 224,385 183,077 3,822,158

 In light of the voting results, our board of directors has determined to hold an advisory vote on executive compensation every year until the next required say-on-frequency vote.

 Proposal 5 : Our stockholders approved, in accordance with Nasdaq rules, the potential future issuance of shares of our common stock under our existing equity line with Lincoln Park Capital Fund, LLC by the votes set forth below.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 3,771,709 325,568 58,444 3,822,158

 Proposal 6 : Our stockholders approved the 2022 Plan Amendment by the votes set forth below.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 3,497,228 609,746 48,747 3,822,158

 Proposal 7 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 5 if there were not sufficient votes to approve Proposal 5 by the votes set forth below. Because Proposal 5 was approved, the adjournment authorized by Proposal 7 was not necessary.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 3,650,815 448,085 56,821 3,822,158

 Proposal 8 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there were not sufficient votes to approve Proposal 6 by the votes set forth below. Because Proposal 6 was approved, the adjournment authorized by Proposal 8 was not necessary.

 Votes For
 Votes Against
 Abstentions
 Broker Non-Votes

 3,531,653 570,999 53,069 3,822,158

 Item 9.01 Financial Statements and Exhibits.

 (d) Exhibits.

 Exhibit No. Description
 10.1 Amendment No. 2 to Daré Bioscience, Inc. 2022 Stock Incentive Plan

 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  

     DARÉ BIOSCIENCE, INC.
  

 Dated: June 12, 2026     By:   /s/ Sabrina Martucci Johnson
     Name:   Sabrina Martucci Johnson
     Title:   President and Chief Executive Officer